RGNXbenzinga

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

Summary

RegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on June 5, 2025 by benzinga